Women Benefit More From Implantable Defibrillators Than Men
By Lori Solomon HealthDay Reporter
TUESDAY, Sept. 2, 2025 -- There is a lower risk of one-year ventricular arrhythmias or death in women with nonischemic cardiomyopathy and an implantable cardioverter defibrillator (ICD) compared with men, according to a study published in the August issue of eClinicalMedicine.
Valentina Kutyifa, M.D., Ph.D., from University of Rochester Medical Center in New York, and colleagues conducted a prespecified interim analysis of the BIO-LIBRA study to assess characteristics, medical therapy, and ventricular tachyarrhythmias (VT/VF) or mortality at 12 months in 1,000 patients with nonischemic cardiomyopathy and ICD or a cardiac resynchronization therapy defibrillator (CRT-D).
The researchers found that women had a lower risk for VT/VF or death versus men through 12 months (hazard ratio [HR], 0.49), driven by a lower risk for VT/VF (HR, 0.46). These associations persisted even after adjustments for left ventricular ejection fraction or QRS duration. There were no significant differences reported by ICD versus CRT-D.
"This is the first study that had a large enough number of females enrolled to show this difference," Kutyifa said in a statement. "We learned that patients with nonischemic cardiomyopathy do well with these devices, but they still have a residual risk of developing life-threatening ventricular arrhythmias or dying, and this risk is lower in females."
Several authors disclosed ties to BIOTRONIK, which funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2025
Read this next
Use of AI Can Help Identify Coronary Thin-Cap Fibroatheromas
TUESDAY, Sept. 2, 2025 -- An artificial intelligence (AI)-based image analysis can identify coronary thin-cap fibroatheromas (TCFAs), which are associated with adverse...
Spironolactone Does Not Reduce Risk for Cardiovascular Morbidity, Mortality in Patients on Dialysis
THURSDAY, Aug. 28, 2025 -- Spironolactone does not reduce a composite outcome of cardiovascular mortality and hospitalization due to heart failure among patients receiving...
Shared, Sex-Specific Body Fat Patterns Linked to Cardiovascular Aging
WEDNESDAY, Aug. 27, 2025 -- Shared and sex-specific patterns of body fat are associated with changes in cardiovascular aging, according to a study published online Aug. 22 in the...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.